Clinical Trial Update: A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) [Phase 1]

View source ↗

Summary

A Phase 1 study of JNJ-90009530 for relapsed or refractory B-cell non-Hodgkin lymphoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JNJ-90009530

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING